Original Research
Published on 23 Oct 2023
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
in Therapy in Gastroenterology
- 834 views
- 1 citation